📊 JANX Key Takeaways
Is Janux Therapeutics, Inc. (JANX) a Good Investment?
Janux Therapeutics exhibits severely negative unit economics with $3.7M revenue generating $24.4M net losses, signaling minimal commercial traction and unsustainable cash burn of $12.3M quarterly despite early-stage pharma status. While the balance sheet provides a 2-3 year cash runway ($51.8M), deteriorating profitability (net income down 64.7% YoY) and negative free cash flow (-$337.8% FCF margin) indicate shareholder value destruction accelerating at an alarming pace.
Janux Therapeutics shows very strong balance-sheet quality, with nearly $957M of equity, minimal liabilities, no meaningful debt, and exceptionally high liquidity that supports ongoing R&D funding. However, the business remains deeply unprofitable, with extremely negative operating and net margins, declining revenue, and significant cash burn, so the core fundamental case still depends on future pipeline execution rather than current operating performance.
Janux Therapeutics, Inc. Key Strengths (JANX)
- Fortress balance sheet with $941.5M stockholders' equity and zero long-term debt
- Exceptional liquidity position (17.01x current ratio) providing operational runway
- Low leverage (0.00x debt-to-equity) with minimal near-term refinancing risk
- Exceptional liquidity with current and quick ratios of 39.04x
- Very strong capitalization with $956.82M in equity and negligible leverage
- Large asset base and low liabilities provide flexibility to sustain development spending
JANX Stock Risks: Janux Therapeutics, Inc. Investment Risks
- Accelerating losses with net income declining 64.7% YoY despite nominal revenue base
- Severe cash burn of $12.3M operating outflow quarters unsustainable without revenue inflection
- Minimal revenue generation ($3.7M) with negative 5.6% YoY trend suggesting market adoption failure
- Operating margin of -916.5% indicates business model fundamentally broken at current stage
- Severe ongoing losses with operating income of -$157.67M and net margin of -1136.2%
- Negative free cash flow of -$83.28M indicates continued cash burn
- Revenue base is small and declined 5.6% YoY, limiting evidence of durable commercial traction
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining runway given current equity burn
- Revenue growth trajectory and clinical pipeline advancement toward commercialization
- Gross margin and unit economics upon achieving meaningful revenue scale
- Quarterly operating cash burn relative to cash reserves
- Revenue growth quality from collaborations, milestones, or product commercialization progress
Janux Therapeutics, Inc. (JANX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.01x current ratio provides a solid financial cushion.
JANX Profit Margin, ROE & Profitability Analysis
JANX vs Healthcare Sector: How Janux Therapeutics, Inc. Compares
How Janux Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Janux Therapeutics, Inc. Stock Overvalued? JANX Valuation Analysis 2026
Based on fundamental analysis, Janux Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Janux Therapeutics, Inc. Balance Sheet: JANX Debt, Cash & Liquidity
JANX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Janux Therapeutics, Inc.'s revenue has grown significantly by 191% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
JANX Revenue Growth, EPS Growth & YoY Performance
JANX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$23.5M | $-0.38 |
| Q3 2025 | $439.0K | -$24.3M | $-0.39 |
| Q2 2025 | N/A | -$6.0M | $-0.11 |
| Q1 2025 | N/A | -$14.8M | $-0.30 |
| Q3 2024 | $439.0K | -$11.6M | $-0.25 |
| Q2 2024 | $1.1M | -$6.0M | $-0.11 |
| Q1 2024 | $1.3M | -$14.8M | $-0.30 |
| Q3 2023 | $1.8M | -$11.6M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Janux Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
JANX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Janux Therapeutics, Inc. (CIK: 0001817713)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JANX
What is the AI rating for JANX?
Janux Therapeutics, Inc. (JANX) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JANX's key strengths?
Claude: Fortress balance sheet with $941.5M stockholders' equity and zero long-term debt. Exceptional liquidity position (17.01x current ratio) providing operational runway. ChatGPT: Exceptional liquidity with current and quick ratios of 39.04x. Very strong capitalization with $956.82M in equity and negligible leverage.
What are the risks of investing in JANX?
Claude: Accelerating losses with net income declining 64.7% YoY despite nominal revenue base. Severe cash burn of $12.3M operating outflow quarters unsustainable without revenue inflection. ChatGPT: Severe ongoing losses with operating income of -$157.67M and net margin of -1136.2%. Negative free cash flow of -$83.28M indicates continued cash burn.
What is JANX's revenue and growth?
Janux Therapeutics, Inc. reported revenue of $3.7M.
Does JANX pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
Where can I find JANX SEC filings?
Official SEC filings for Janux Therapeutics, Inc. (CIK: 0001817713) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JANX's EPS?
Janux Therapeutics, Inc. has a diluted EPS of $-0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is JANX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Janux Therapeutics, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is JANX stock overvalued or undervalued?
Valuation metrics for JANX: ROE of -2.6% (sector avg: 15%), net margin of -652.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is JANX's AI grade for 2026?
Our dual AI analysis gives Janux Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JANX's free cash flow?
Janux Therapeutics, Inc.'s operating cash flow is $-12.3M, with capital expenditures of $273.0K. FCF margin is -337.8%.
How does JANX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -652.6% (avg: 12%), ROE -2.6% (avg: 15%), current ratio 17.01 (avg: 2).